Journal of Kidney Cancer and VHL最新文献

筛选
英文 中文
Precision Medicine: Seeing the Tree in the Forest!
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-03-07 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.395
Ulka Vaishampayan
{"title":"Precision Medicine: Seeing the Tree in the Forest!","authors":"Ulka Vaishampayan","doi":"10.15586/jkc.v12i1.395","DOIUrl":"10.15586/jkc.v12i1.395","url":null,"abstract":"","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"27-28"},"PeriodicalIF":1.9,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11894122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143606637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systematic Review of Robotic Nephrectomy for Kidney Cancer.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-03-05 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.372
Danilo Coco, Silvana Leanza, Massimo Giuseppe Viola, Desideria Coco
{"title":"Systematic Review of Robotic Nephrectomy for Kidney Cancer.","authors":"Danilo Coco, Silvana Leanza, Massimo Giuseppe Viola, Desideria Coco","doi":"10.15586/jkc.v12i1.372","DOIUrl":"https://doi.org/10.15586/jkc.v12i1.372","url":null,"abstract":"<p><p>Robotic nephrectomy has become an increasingly preferred surgical technique for managing renal cell carcinoma (RCC). This review aims to systematically evaluate existing literature on the safety, efficacy, clinical outcomes, and associated costs of robotic nephrectomy, especially in relation to tumor dimensions and other pertinent patient factors. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we performed an extensive literature search across major databases (PubMed, Scopus, and Cochrane Library) from inception to October 2023. The inclusion criteria encompassed randomized controlled trials (RCTs), cohort studies, and case-control studies that compared robotic nephrectomy with open or laparoscopic nephrectomy. Outcomes analyzed included operative time, intraoperative blood loss, complication rates, length of hospital stay, oncological outcomes, and cost-effectiveness. The Egger test was used to assess publication bias. The review incorporated 30 studies involving 5,432 patients who underwent robotic nephrectomy. Key findings indicated that robotic nephrectomy resulted in significantly reduced intraoperative blood loss (mean difference of -85 mL; p < 0.001) and shorter hospital stays (mean difference of -1.3 days). Tumor size had a notable impact on surgical outcomes, with larger tumors (≥7 cm) being associated with prolonged operative times and slightly higher complication rates. Robotic nephrectomy was also associated with higher costs compared to conventional surgical techniques; however, reduced readmission rates offset some of these costs. Oncological outcomes for robotic nephrectomy were comparable to those of open nephrectomy. Robotic nephrectomy is a safe and effective approach for kidney cancer that demonstrates advantages in perioperative recovery and surgical precision, particularly for smaller tumors. While costs may be higher, the clinical benefits and potential long-term savings from decreased postoperative complications recommend its use. Further high-quality RCTs are essential to validate these findings.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"29-35"},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11909633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Case of Bilateral Adrenal Tumors Confirms Pathogenicity of Previously Described c.463+4C>G Variant in the von-Hippel Lindau Gene.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-03-01 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.381
Samuel Morriss, Victoria Beshay, Huei San Leong, Ingrid Winship
{"title":"Novel Case of Bilateral Adrenal Tumors Confirms Pathogenicity of Previously Described c.463+4C>G Variant in the von-Hippel Lindau Gene.","authors":"Samuel Morriss, Victoria Beshay, Huei San Leong, Ingrid Winship","doi":"10.15586/jkc.v12i1.381","DOIUrl":"10.15586/jkc.v12i1.381","url":null,"abstract":"<p><p>We report a case of a pathogenic variant c.463+4C>G in the von Hippel-Lindau (VHL) gene identified in a patient presenting with bilateral adrenal tumors, including a histologically confirmed pheochromocytoma with no significant family history of VHL-associated tumors. This same variant was first reported as having pathogenic significance in an unrelated proband with a hemangioblastoma and a family history of pheochromocytoma. In our patient, next-generation sequencing and subsequent RNA (ribonucleic acid) analysis confirmed this mutation to be a pathogenic (class 4) variant in intron 2. The lack of family history of VHL-associated tumors correlated with the proband further suggests that this mutation may have reduced penetrance. This case confirms the pathogenicity of the same previously described variant in the VHL gene and underscores the utility of genetic testing in patients with atypical presentations of adrenal tumors, even in the absence of a relevant family history.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"23-26"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of BCL11A, NTN5, and OGN as Diagnosis Biomarker of Papillary Renal Cell Carcinomas by Bioinformatic Analysis.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-02-28 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.366
Zahra Haghshenas, Sina Fathi, Alireza Ahmadzadeh, Elham Nazari
{"title":"Identification of BCL11A, NTN5, and OGN as Diagnosis Biomarker of Papillary Renal Cell Carcinomas by Bioinformatic Analysis.","authors":"Zahra Haghshenas, Sina Fathi, Alireza Ahmadzadeh, Elham Nazari","doi":"10.15586/jkc.v12i1.366","DOIUrl":"10.15586/jkc.v12i1.366","url":null,"abstract":"<p><p>The prevalence of papillary renal cell carcinomas (PRCCs) is estimated to be between 10% and 15%. At present, there is no effective therapeutic approach available for patients with advanced PRCCs. The molecular biomarkers associated with PRCC diagnoses have been rarely studied compared to renal clear cell carcinomas; therefore, the necessity for the identification of novel molecular biomarkers to aid in the early identification of this disease. Bioinformatics and artificial intelligence technologies have become increasingly important in the search for diagnostic biomarkers for early cancer detection. In this study, three genes-BCL11A, NTN5, and OGN-were identified as diagnostic biomarkers using the Cancer Genome Atlas (TCGA) database and deep learning techniques. To identify the differential expression genes (DEGs), ribonucleic acid (RNA) expression profiles of PRCC patients were analyzed using a machine learning approach. A number of molecular pathways and coexpressions of DEGs have been analyzed and a correlation between DEGs and clinical data has been determined. Diagnostic markers were then determined via machine learning analysis. The 10 genes selected with the highest variable importance value (more than 0.9) were further investigated, with six upregulated (BCL11A, NTN5, SEL1L3, SKA3, TAPBP, SEMA6A) and four downregulated (OGN, ADCY4, SMOC2, CCL23). A combined receiver operating characteristic (ROC) curve analysis revealed that the BCL11A-NTN5-OGN genes, which have specificity and sensitivity values of 0.968 and 0.901, respectively, can be used as a diagnostic biomarker for PRCC. In general, the genes introduced in this study may be used as diagnostic biomarkers for the early diagnosis of PRCC, thus providing the possibility of early treatment and preventing the progression of the disease.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"12-22"},"PeriodicalIF":1.9,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11884337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucinous Tubular and Spindle Cell Carcinoma: Case Report and Literature Review.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-02-25 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.354
S L Tsang, S S Hsu, Cheung An, Shb Ho, Atl Ng
{"title":"Mucinous Tubular and Spindle Cell Carcinoma: Case Report and Literature Review.","authors":"S L Tsang, S S Hsu, Cheung An, Shb Ho, Atl Ng","doi":"10.15586/jkc.v12i1.354","DOIUrl":"https://doi.org/10.15586/jkc.v12i1.354","url":null,"abstract":"<p><p>Mucinous tubular and spindle cell carcinoma (MTSCC) is a rare type of renal cell carcinoma (RCC) recognized as an independent entity in the latest WHO (World Health Organization) classification. We here report a case of a 51-year-old female patient with MTSCC, who presented with abdominal pain and left lower pole kidney lesion on the computed tomography scan. A robotic-assisted laparoscopic partial nephrectomy was performed. The diagnosis was confirmed on histopathological examination. MTSCC is rare and generally indolent. Either partial or radical nephrectomy is usually curative. The prognosis is usually favorable. However, occasionally, MTSCC could demonstrate aggressive features requiring systemic therapy. There are also several mimickers of MTSCC, which carry different prognostic and treatment profiles. Histological, immunohistochemical, and molecular genetic profile are useful in diagnosing the disease.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"6-11"},"PeriodicalIF":1.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Journal of Kidney Cancer wishes to inform its readers that the following article has been officially retracted.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-02-19 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.392
{"title":"The <i>Journal of Kidney Cancer</i> wishes to inform its readers that the following article has been officially retracted.","authors":"","doi":"10.15586/jkc.v12i1.392","DOIUrl":"https://doi.org/10.15586/jkc.v12i1.392","url":null,"abstract":"<p><p>[This retracts the article DOI: 10.15586/jkcvhl.v10i1.232.].</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"5"},"PeriodicalIF":1.9,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11840175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identifying Hereditary Leiomyomatosis and Renal Cell Cancer through Unobtrusive Cutaneous Nodules: A Clinical Report.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2025-01-27 eCollection Date: 2025-01-01 DOI: 10.15586/jkc.v12i1.374
Emilija Šeštokaitė, Eglė Preikšaitienė, Justas Arasimavičius
{"title":"Identifying Hereditary Leiomyomatosis and Renal Cell Cancer through Unobtrusive Cutaneous Nodules: A Clinical Report.","authors":"Emilija Šeštokaitė, Eglė Preikšaitienė, Justas Arasimavičius","doi":"10.15586/jkc.v12i1.374","DOIUrl":"10.15586/jkc.v12i1.374","url":null,"abstract":"<p><p>Cutaneous leiomyomas (CLMs) are associated with Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome (Mendelian Inheritance in Man [MIM]: 150800)-a rare genodermatosis caused by a heterozygous pathogenic variant in the fumarate hydratase (<i>FH</i>) gene. It is characterized by a predisposition to develop cutaneous and/or uterine leiomyomas and an aggressive type of renal cell carcinoma (RCC). We describe a 27-year-old male who presented with a painful nodule on the left upper arm persisting for 5 years and the subsequent emergence of painless nodules in various parts of the body over the past two years. A family history of RCC prompted suspicion of the HLRCC syndrome. Cutaneous examination revealed erythematous subcutaneous nodules, with histological analysis confirming CLM. Genetic testing identified a pathogenic variant in the <i>FH</i> gene, confirming the diagnosis of HLRCC. Management involved surgical excision of the symptomatic nodules and genetic counselling/testing for the proband and his family members. The long-term follow-up plan includes dermatological and nephrological surveillance with annual renal magnetic resonance imaging (MRI) scans. This report aims to enhance the awareness of this disease and highlight the role of cutaneous lesions in facilitating early detection.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"12 1","pages":"1-4"},"PeriodicalIF":1.9,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between ZHX2 Expression and VHL Gene Alteration in VHL-associated and Sporadic Hemangioblastomas of the Central Nervous System.
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2024-12-31 eCollection Date: 2024-01-01 DOI: 10.15586/jkcvhl.v11i4.355
Hiroshi Kanno, Kimihiro Nakahara, Sachiko Yamada, Satoshi Fujii, Hidetoshi Murata, Tetsuya Yamamoto, Hisashi Hasumi, Masahiro Yao
{"title":"Relationship between ZHX2 Expression and VHL Gene Alteration in VHL-associated and Sporadic Hemangioblastomas of the Central Nervous System.","authors":"Hiroshi Kanno, Kimihiro Nakahara, Sachiko Yamada, Satoshi Fujii, Hidetoshi Murata, Tetsuya Yamamoto, Hisashi Hasumi, Masahiro Yao","doi":"10.15586/jkcvhl.v11i4.355","DOIUrl":"10.15586/jkcvhl.v11i4.355","url":null,"abstract":"<p><p>Central nervous system hemangioblastoma (CNS-HB) is the most common manifestation of von Hippel-Lindau disease (VHL). The main axis of the CNS-HB pathway is the VHL-HIF signaling pathway. Recently, we proposed an alternative VHL-JAK-STAT pathway in CNS-HB. In contrast, the VHL substrate transcription factor zinc fingers and homeoboxes 2 (ZHX2) have been identified as the oncogenic drivers in VHL-deficient clear cell renal cell carcinoma (RCC). However, ZHX2 expression in CNS-HB has not been previously reported. Furthermore, the VHL-ZXH2-NF-κB signaling pathway in CNS-HB remains unresolved. In this study, we aimed to investigate ZHX2 expression and VHL gene alteration in CNS-HB and propose the role of ZHX2 in CNS-HB. Using the MACS method, Scl+ hemangioblastoma-like cells were isolated from multipotent nestin-expressing stem cells. The ubiquitination of ZHX2 in these cells and the immunoprecipitation between ZHX2 and VHL were investigated. In addition, the VHL genes of patients with hemangioblastoma were analyzed. ZHX2 expression in CNS-HB tissues was examined by immunohistochemistry and western blotting. In addition, VHL gene mutations in CNS-HB were analyzed by sequencing. The association between ZHX2 expression and VHL gene mutation was analyzed. ZHX2 was ubiquitinated in Scl+hemangioblastoma-like cells after the transfer of the VHL expression vector into these cells. ZHX2 expression in these cells was well detected before transfer but disappeared after the transfer. ZHX2 expression was detected in 18 of the 21 CNS-HB tissues by immunoblotting and/or immunohistochemistry. Sporadic CNS-HB showed weak expression, whereas VHL-related CNS-HB showed moderate or strong expression. In particular, CNS-HB with severe VHL gene mutations, including large deletions, showed strong or moderate ZHX2 expression. The association between VHL gene mutation and ZHX2 expression revealed a significant correlation between VHL gene alteration severity and the level of immunoblotting (P < 0.05). In conclusion, the severity of VHL gene alteration correlates with the level of ZHX2 expression. ZHX2 is predominantly expressed in CNS-HB, especially in VHL-related cases with severe VHL gene alterations, suggesting a potential role in tumorigenesis and proliferation of CNS-HB.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"11 4","pages":"39-47"},"PeriodicalIF":1.9,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau? TriNetX数据库是研究Von Hippel-Lindau真实世界管理的好工具吗?
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2024-12-10 eCollection Date: 2024-01-01 DOI: 10.15586/jkcvhl.v11i4.324
Aaron R Hochberg, Patrick T Gomella, Brian Im, Anushka Ghosh, Sohan Shah, Rasheed A M Thompson, Kevin K Zarrabi, Mihir S Shah, J Ryan Mark, Joseph K Izes, Costas D Lallas, Leonard G Gomella, Adam R Metwalli
{"title":"Is the TriNetX Database a Good Tool for Investigation of Real-World Management of Von Hippel-Lindau?","authors":"Aaron R Hochberg, Patrick T Gomella, Brian Im, Anushka Ghosh, Sohan Shah, Rasheed A M Thompson, Kevin K Zarrabi, Mihir S Shah, J Ryan Mark, Joseph K Izes, Costas D Lallas, Leonard G Gomella, Adam R Metwalli","doi":"10.15586/jkcvhl.v11i4.324","DOIUrl":"10.15586/jkcvhl.v11i4.324","url":null,"abstract":"<p><p>Von Hippel-Lindau (vHL) is a hereditary disease characterized by the development of benign and malignant tumors across multiple organ systems. It is seen in approximately 1 in 36,000 live births. Given that vHL is a rare disease, studies that seek to characterize vHL are often hampered by small sample sizes. The TriNetX database, which contains data from over 100 million patients, may offer the ability to define and describe a large number of vHL patients. The primary objectives of this study were to describe the prevalence of vHL-associated conditions and investigate clinical outcomes using TriNetX. The secondary objective was to compare the results of this analysis to what has been reported in the published vHL literature. TriNetX was queried to establish a cohort of patients with a diagnosis of vHL. This cohort was then used to define the prevalence of the following conditions: reproductive organ (epididymal and broad ligament) cystadenomas, renal cell carcinoma (RCC), pheochromocytomas, endolymphatic sac tumors (ESLTs), central nervous system (CNS) and retinal hemangioblastomas, and pancreatic neuroendocrine tumor (pNETs). A total of 1232 patients in TriNetX had a recorded diagnosis of vHL. Of this, 34 (6.0% of males) patients had epididymal cystadenoma, 21 (3.4% of females) had broad ligament cystadenoma, 352 (28.6%) had RCC, 251 (20.4%) had pheochromocytoma, <10 had ELST, 171 (13.9%) had CNS hemangioblastoma, 34 (2.8%) had pNETs, and 66 (5.4%) had retinal hemangioma. Compared to the existing literature, vHL and associated conditions are underdiagnosed in TriNetX, suggesting its limited use in studying this disease.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"11 4","pages":"28-38"},"PeriodicalIF":1.9,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11638858/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany. 对患有与 von Hippel-Lindau (VHL) 相关的嗜铬细胞瘤和副神经节瘤的儿童和青少年进行监测:德国 MET 和 Freiburg-VHL 登记处调查。
IF 1.9
Journal of Kidney Cancer and VHL Pub Date : 2024-11-20 eCollection Date: 2024-01-01 DOI: 10.15586/jkcvhl.v11i4.362
Fruzsina Kotsis, Marina Kunstreich, Antje Redlich, Kilian Rhein, Athina Ganner, Gerd Walz, Michaela Kuhlen, Elke Neumann-Haefelin
{"title":"Surveillance in Children and Adolescents with von Hippel-Lindau (VHL)-Related Pheochromocytomas and Paragangliomas: A Survey of MET and Freiburg-VHL Registries in Germany.","authors":"Fruzsina Kotsis, Marina Kunstreich, Antje Redlich, Kilian Rhein, Athina Ganner, Gerd Walz, Michaela Kuhlen, Elke Neumann-Haefelin","doi":"10.15586/jkcvhl.v11i4.362","DOIUrl":"10.15586/jkcvhl.v11i4.362","url":null,"abstract":"<p><p>Early identification of patients at risk with von Hippel-Lindau (VHL) syndrome-related pheochromocytoma and paraganglioma (PPGL) is crucial to prevent morbidity. We investigated the current surveillance recommendations in VHL-related PPGL in children and adolescents. German Pediatric Oncology and Hematology-Malignant Endocrine Tumor registry (GPOH-MET) and Freiburg-VHL registry (1996-2022). In all, 75 patients (aged 0-18 years) with VHL syndrome were analyzed and 52 were in the Freiburg screening/surveillance program (median follow-up: 11.5 ± 0.94 years), including annual hormone level measurements, eye examination (starting at the age 6 years), and MRI of the abdomen and central nervous system (CNS) (starting at the age of 12 years). Retrospective analysis of clinical outcomes and descriptive statistics was performed. Of the 75 patients, 60 had a previous clinical diagnosis of PPGL with subsequent genetic testing, and 63% had a positive family history. In spite of having positive family history, large variations of timings between genetic and clinical diagnosis (range: -9 to +40 years) were observed. The mean age of first PPGL was 12.4 ± 0.41 years (range: 4-18 years). Recurrence of PPGL was common (46%; range: 2-7 per patient), and that of other tumors occurred: hemangioblastomas (73%), retinal angiomas (58%), renal cell carcinomas (21%), and pancreatic neuroendocrine tumors (12%). VHL-related PPGL appeared by the age of 12 and recurrences were observed frequently. Hemangioblastomas and retinal angiomas were common. In spite of a positive family history, VHL diagnoses were delayed. Because of high tumor proportions of affected families with children, it needs an optimization of the surveillance framework to enhance compliance and minimize anxiety and worse disease outcomes.</p>","PeriodicalId":44291,"journal":{"name":"Journal of Kidney Cancer and VHL","volume":"11 4","pages":"15-27"},"PeriodicalIF":1.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11586502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信